Source comparison
CJC-1295 no DAC & Ipamorelin Research Review: Comparison
The table below compares CJC-1295 no DAC & Ipamorelin against alternative growth hormone secretagogue combinations used in contemporary research protocols. Each pairing targets GH release through distinct mechanisms—but not all demonstrate synergy, and off-tar
This comparison does not assign a generated winner or score.
- The table below compares CJC-1295 no DAC & Ipamorelin against alternative growth hormone secretagogue combinations used in contemporary research protocols. Each pairing targets GH release through distinct mechanisms—but not all demonstrate synergy, and off-target effects vary significantly.
- CJC-1295 no DAC + Ipamorelin
- GHRH receptor agonist + selective GHSR-1a agonist
- 3–5× GH AUC vs monotherapy (rodent models)
- None documented at standard doses
- Body composition, aging, metabolic studies
- Gold standard for synergy without cortisol/prolactin elevation—most researched pairing
- Sermorelin + GHRP-2
- Short-acting GHRH + non-selective ghrelin mimetic
- 2–3× GH AUC vs monotherapy
- Cortisol +20–30%, prolactin +15–25%, increased hunger
- Sleep quality, recovery protocols
- Effective but off-target effects limit long-term use
- CJC-1295 DAC + Hexarelin
- Long-acting GHRH + potent ghrelin mimetic
- High initial response, diminishes after 4–6 weeks
- Cortisol elevation, prolactin spike, desensitization risk
- Older research protocols (pre-2010)
- Potent but tolerance develops—no DAC variants preferred
- Tesamorelin + Ipamorelin
- Synthetic GHRH (HIV lipodystrophy approved) + selective GHSR-1a
- Documented in HIV lipodystrophy trials
- Minimal—Tesamorelin FDA-approved profile clean
- Visceral fat reduction, metabolic syndrome
- Clinically validated but less GH amplitude than CJC no DAC
- MK-677 (Ibutamoren) monotherapy
- Oral ghrelin mimetic (non-peptide)
- Sustained GH elevation but non-pulsatile
- Increased appetite, fasting glucose +5–10 mg/dL, water retention
- Sarcopenia, frailty studies
- Convenient but disrupts natural pulsatility—not synergistic
- The bottom line: CJC-1295 no DAC & Ipamorelin offer the cleanest side-effect profile and the strongest preclinical evidence for synergistic GH release among peptide secretagogue combinations. The absence of cortisol and prolactin elevation makes this pairing suitable for extended research protocols where hypothalamic-pituitary-adrenal (HPA) axis disruption would confound metabolic or body composition endpoints. For researchers requiring FDA-approved reference compounds, Tesamorelin provides a clinically validated GHRH analog, though its GH pulse amplitude is lower than CJC-1295 no DAC in head-to-head pharmacokinetic studies.